Synergistic anti-tumor effects of combination of photodynamic therapy and arsenic compound in cervical cancer cells: In vivo and in vitro studies

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Kim, Yong Wan ^a   Bae, Su Mi ^a   Battogtokh, Gantumur ^a   Bang, Hyo Joo ^a   Ahn, Woong Shick ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC DERIVATIVE; PHOTOSENSITIZING AGENT; PROTEIN P53; RADACHLORIN; TETRAARSENIC OXIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; ARSENIC TETRAOXIDE; ORGANOARSENIC DERIVATIVE; OXIDE; TUMOR PROTEIN;

ADJUVANT THERAPY; AIP1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BAX GENE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CD178 GENE; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME SYNTHESIS; FAS GENE; GADD45 GENE; GENE INDUCTION; HUMAN; HUMAN CELL; IGFBP 3 GENE; IL2 GENE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LY 12 GENE; MDM 2 GENE; MONOTHERAPY; MOUSE; NAIP GENE; NONHUMAN; P21 GENE; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; TERT GENE; TREATMENT RESPONSE; TUMOR GENE; UTERINE CERVIX CANCER; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS;

ANIMALS; ARSENICALS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; OXIDES; PHOTOCHEMOTHERAPY; UTERINE CERVICAL NEOPLASMS;

EID: 84862001784     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038583     Document Type: Article

References (40)

1. Al-Waili NS, Butler GJ, Beale J, Hamilton RW, Lee BY, et al. (2005) Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy. Med Sci Monit 11: RA279-289.
2. Moserova I, Kralova J, (2012) Role of ER Stress Response in Photodynamic Therapy: ROS Generated in Different Subcellular Compartments Trigger Diverse Cell Death Pathways. PLoS One 7: e32972.
3. Corti L, Mazzarotto R, Belfontali S, De Luca C, Baiocchi C, et al. (1996) Photodynamic therapy in gynaecological neoplastic diseases. J Photochem Photobiol B 36: 193-197.
4. Gomer CJ, Rucker N, Ferrario A, Wong S, (1989) Properties and applications of photodynamic therapy. Radiat Res 120: 1-18.
5. Wei Y, Kong B, Song K, Qu X, Jin Q, et al. (2007) Involvement of mitochondria-caspase pathway in Hemoporfin-mediated cell death. Photochem Photobiol 83: 1319-1324.
6. Separovic D, Bielawski J, Pierce JS, Merchant S, Tarca AL, et al. (2009) Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas. Br J Cancer 100: 626-632.
7. Cheung WM, Chu PW, Kwong YL, (2007) Effects of arsenic trioxide on the cellular proliferation, apoptosis and differentiation of human neuroblastoma cells. Cancer Lett 246: 122-128.
8. Woo SH, Park MJ, An S, Lee HC, Jin HO, et al. (2005) Diarsenic and tetraarsenic oxide inhibit cell cycle progression and bFGF- and VEGF-induced proliferation of human endothelial cells. J Cell Biochem 95: 120-130.
9. Yoo MH, Kim JT, Rhee CH, Park MJ, Bae IJ, et al. (2004) Reverse effects of tetraarsenic oxide on the angiogenesis induced by nerve growth factor in the rat cornea. J Vet Med Sci 66: 1091-1095.
10. Ahn WS, Bae SM, Lee KH, Kim YW, Lee JM, et al. (2004) Comparison of effects of As2O3 and As4O6 on cell growth inhibition and gene expression profiles by cDNA microarray analysis in SiHa cells. Oncol Rep 12: 573-580.
11. Liu LZ, Jiang Y, Carpenter RL, Jing Y, Peiper SC, et al. (2011) Role and mechanism of arsenic in regulating angiogenesis. PLoS One 6: e20858.
12. Germolec DR, Yoshida T, Gaido K, Wilmer JL, Simeonova PP, et al. (1996) Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol Appl Pharmacol 141: 308-318.
13. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, et al. (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88: 1052-1061.
14. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, et al. (1998) Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90: 124-133.
15. Banerjee N, Banerjee M, Ganguly S, Bandyopadhyay S, Das JK, et al. (2008) Arsenic-induced mitochondrial instability leading to programmed cell death in the exposed individuals. Toxicology 246: 101-111.
16. Laparra JM, Velez D, Barbera R, Farre R, Montoro R, (2008) As2O3-induced oxidative stress and cycle progression in a human intestinal epithelial cell line (Caco-2). Toxicol In Vitro 22: 444-449.
17. Rigas B, Sun Y, (2008) Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Br J Cancer 98: 1157-1160.
18. Rigas B, (2007) The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia. Curr Opin Gastroenterol 23: 55-59.
19. Gao J, Liu X, Rigas B, (2005) Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci U S A 102: 17207-17212.
20. Sun Y, Rigas B, (2008) The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 68: 8269-8277.
21. Buytaert E, Dewaele M, Agostinis P, (2007) Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 1776: 86-107.
22. Sagawa Y, Nishi H, Isaka K, Fujito A, Takayama M, (2001) The correlation of TERT expression with c-myc expression in cervical cancer. Cancer Lett 168: 45-50.
23. Castano AP, Mroz P, Hamblin MR, (2006) Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6: 535-545.
24. Kammerer R, Buchner A, Palluch P, Pongratz T, Oboukhovskij K, et al. (2011) Induction of immune mediators in glioma and prostate cancer cells by non-lethal photodynamic therapy. PLoS One 6: e21834.
25. Solban N, Selbo PK, Sinha AK, Chang SK, Hasan T, (2006) Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Res 66: 5633-5640.
26. Nakagawa H, Matsumiya T, Sakaki H, Imaizumi T, Kubota K, et al. (2007) Expression of vascular endothelial growth factor by photodynamic therapy with mono-L-aspartyl chlorin e6 (NPe6) in oral squamous cell carcinoma. Oral Oncol 43: 544-550.
27. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, et al. (2000) Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 60: 4066-4069.
28. Ferrario A, Von Tiehl K, Wong S, Luna M, Gomer CJ, (2002) Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 62: 3956-3961.
29. Ferrario A, Fisher AM, Rucker N, Gomer CJ, (2005) Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 65: 9473-9478.
30. Ferrario A, Chantrain CF, von Tiehl K, Buckley S, Rucker N, et al. (2004) The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res 64: 2328-2332.
31. Gomer CJ, Ferrario A, Luna M, Rucker N, Wong S, (2006) Photodynamic therapy: combined modality approaches targeting the tumor microenvironment. Lasers Surg Med 38: 516-521.
32. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH, (1999) Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 59: 6033-6037.
33. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, et al. (1999) Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59: 1626-1634.
34. Chou TC, (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446.
35. Pletcher SD, Macdonald SJ, Marguerie R, Certa U, Stearns SC, et al. (2002) Genome-wide transcript profiles in aging and calorically restricted Drosophila melanogaster. Curr Biol 12: 712-723.
36. Wang JL, Lin YW, Chen HM, Kong X, Xiong H, et al. (2011) Calcium prevents tumorigenesis in a mouse model of colorectal cancer. PLoS One 6: e22566.
37. Goodwin SC, Bonilla SC, Sacks D, Reed RA, Spies JB, et al. (2003) Reporting standards for uterine artery embolization for the treatment of uterine leiomyomata. J Vasc Interv Radiol 14: S467-476.
38. Tomayko MM, Reynolds CP, (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148-154.
39. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
40. Reynolds CP, Maurer BJ, (2005) Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med 110: 173-183.